Additional Risks Of I.V. Anticonvulsants To Be Taken Up By FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
A joint advisory committee will determine if regulatory action is necessary to reduce risks from intravenous administration of phenytoin and fosphenytoin, including the risk of a skin disease that can lead to amputation.